Otrivin Advance (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline hydrochloride and Ipratropium bromide, the active ingredients in Otrivin Advance, are nasal decongestants presented as a nasal spray for topical intranasal use. They relieve swelling of the nasal mucosa and reduce secretions, providing rapid relief of congestion in adults and children over six years of age.

GNH USA supplies Otrivin Advance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otrivin Advance, containing xylometazoline and ipratropium, acts on nasal vascular smooth muscle and muscarinic receptors to alleviate congestion.

Acute nasal congestion: rapid reduction of swelling in the nasal passages. Allergic rhinitis: helps relieve congestion associated with allergic inflammation. Common cold: eases nasal blockage during viral upper respiratory infection.

Adverse reactions may occur with intranasal use of Otrivin Advance.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Bitter taste - Headache - Minor nosebleeds (epistaxis)

Serious or Rare Side Effects: - Rebound congestion (rhinitis medicamentosa) with prolonged use - Severe nasal ulceration or perforation - Allergic reactions including rash, angioedema, or anaphylaxis - Increased intra‑ocular pressure in susceptible individuals - Rare cardiac arrhythmias due to systemic absorption of the alpha‑agonist

Before using Otrivin Advance, consider the following safety measures.

Pregnancy: consult a healthcare professional before use. Breastfeeding: use only if the benefit outweighs potential risk. Children under 6 years: not recommended. Hypertension: monitor blood pressure during treatment. Glaucoma: avoid use in patients with narrow‑angle glaucoma. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Otrivin Advance may interact with other medicines; review the following categories.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis due to vasoconstriction. - Beta‑blockers: may potentiate vasoconstrictive effects. - Other nasal decongestants: increased risk of rebound congestion.

Moderate Interactions (Monitor Closely): - Antihistamines: additive drying of nasal mucosa. - Systemic anticholinergic agents: heightened anticholinergic load. - Corticosteroid nasal sprays: monitor for local irritation.